Literature DB >> 10737473

Laparoscopic lymphocelectomy: a multi-institutional analysis.

T H Hsu1, I S Gill, M T Grune, R Andersen, D Eckhoff, D A Goldfarb, R Gruessner, E E Hodge, L C Munch, D D Nghiem, A Nye, C R Reckard, T Shaver, R J Stratta, R J Taylor.   

Abstract

PURPOSE: Because symptomatic lymphoceles are infrequent, single center studies generally report small numbers of patients. We report a multi-institutional experience with and long-term outcome following laparoscopic lymphocelectomy in 81 patients.
MATERIALS AND METHODS: Data were obtained from 9 institutions at which at least 5 cases of laparoscopic lymphocelectomy had been performed. Baseline patient demographics, operative time and blood loss, special operative adjunct techniques, postoperative course, convalescence, complications and lymphocele recurrence data were collected and analyzed.
RESULTS: A total of 56 men and 25 women with a mean age of 41 years were included in the study. Lymphocele formed after renal transplantation in 78 patients (96%) and after pelvic lymph node dissection in 3 (4%). Average operating time was 123 minutes with a mean blood loss of 43 ml. Omentopexy was performed in 11 cases (13.6%). No intraoperative stenting of the transplant ureter was performed. Intraoperative complications consisted of laryngospasm, bladder injury, inferior epigastric artery injury and mild renal capsule hematoma in 1 patient each. Conversion to open surgery was required for repair of bladder injury in 1, repair of preexisting hernia in 1, unusually thickened lymphocele wall in 1 and inaccessible lymphocele location in 4 cases. Mean time to ambulation and resumption of regular diet was 1 day, and mean hospital stay was 1.5 days. Postoperative complications included trocar site hernia in 1 and urinary retention in 2. Convalescence averaged 2.5 weeks. During a mean followup of 27 months 5 patients (6%) had lymphocele recurrence.
CONCLUSIONS: Laparoscopic lymphocelectomy is safe, minimally invasive and effective. It is an excellent alternative to the conventional open surgical approach.

Entities:  

Mesh:

Year:  2000        PMID: 10737473     DOI: 10.1016/s0022-5347(05)67700-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Laparoscopic fenestration of posttransplant lymphoceles.

Authors:  C Doehn; P Fornara; L Fricke; D Jocham
Journal:  Surg Endosc       Date:  2001-12-31       Impact factor: 4.584

Review 2.  [Lymphoceles after radical retropubic prostatectomy. A treatment algorithm].

Authors:  P Anheuser; A Treiyer; E Stark; B Haben; J A Steffens
Journal:  Urologe A       Date:  2010-07       Impact factor: 0.639

Review 3.  Laparoscopic treatment of post renal transplant lymphoceles.

Authors:  S H Bailey; M C Mone; J M Holman; E W Nelson
Journal:  Surg Endosc       Date:  2003-10-23       Impact factor: 4.584

4.  Comparison of Postoperative Benign Pelvic Cysts Occurred after Gynecologic or Gyne-oncologic Surgery Treated with Percutaneous Transcatheteric Sclerosant Alcohol Therapy.

Authors:  Cihan Comba; Aysun Erbahceci Salik; Gokhan Demirayak; Sakir Volkan Erdogan; Filiz Sacan; Isa Aykut Ozdemir
Journal:  Gynecol Minim Invasive Ther       Date:  2020-10-15

5.  A Novel Technique Using Fluorescent Ureteral Catheter and Flexible Ureteroscope for Safe Laparoscopic Fenestration of Lymphocele after Kidney Transplantation.

Authors:  Takanori Sekito; Motoo Araki; Koichiro Wada; Kasumi Yoshinaga; Yuki Maruyama; Takuya Sadahira; Satoshi Katayama; Takehiro Iwata; Shingo Nishimura; Tomoko Sako; Kohei Edamura; Yasuyuki Kobayashi; Toyohiko Watanabe
Journal:  Case Rep Transplant       Date:  2022-02-07

Review 6.  Laparoscopy in transplantation.

Authors:  Eduardo Krajewski; Ian S Soriano; Jorge Ortiz
Journal:  JSLS       Date:  2006 Oct-Dec       Impact factor: 2.172

7.  Bleomycin sclerotherapy for severe symptomatic and persistent pelvic lymphocele.

Authors:  Ana Sofia Fernandes; Antónia Costa; Raquel Mota; Vera Paiva
Journal:  Case Rep Obstet Gynecol       Date:  2014-07-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.